Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.
作者信息
Trave Ilaria, Salvi Ilaria, Bagnasco Diego, Parodi Aurora, Cozzani Emanuele
机构信息
Section of Dermatology - Department of Health Sciences, University of Genoa, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy.
Section of Respiratory Diseases and Allergology - Department of Internal Medicine (DIMI), University of Genoa, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy.
出版信息
Acta Derm Venereol. 2024 Sep 19;104:adv40800. doi: 10.2340/actadv.v104.40800.
Abstract
摘要
相似文献
1
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.
Acta Derm Venereol. 2024 Sep 19;104:adv40800. doi: 10.2340/actadv.v104.40800.
2
Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient.
J Dermatolog Treat. 2023 Dec;34(1):2229466. doi: 10.1080/09546634.2023.2229466.
3
Systemic Biologic Management of Atopic Dermatitis.
Adv Exp Med Biol. 2024;1447:139-149. doi: 10.1007/978-3-031-54513-9_13.
4
Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e394-e396. doi: 10.1111/jdv.17177. Epub 2021 Mar 5.
5
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1.
6
Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.
J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):261-263. doi: 10.18176/jiaci.0614. Epub 2020 Jul 30.
7
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
8
Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP.
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4477-4479. doi: 10.1016/j.jaip.2021.07.049. Epub 2021 Aug 9.
9
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series.
Clin Exp Allergy. 2023 May;53(5):586-589. doi: 10.1111/cea.14305. Epub 2023 Mar 16.
10
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.
本文引用的文献
1
Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis.
Front Immunol. 2024 Jan 8;14:1277734. doi: 10.3389/fimmu.2023.1277734. eCollection 2023.
2
Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2666-2671. doi: 10.1016/j.jaip.2023.07.026. Epub 2023 Jul 26.
3
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management.
Expert Rev Respir Med. 2022 Jul;16(7):713-721. doi: 10.1080/17476348.2022.2090342. Epub 2022 Jun 23.
4
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28.
5
Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
J Dermatolog Treat. 2022 Aug;33(5):2587-2592. doi: 10.1080/09546634.2022.2049588. Epub 2022 Mar 9.
6
Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma.
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2913-2915. doi: 10.1016/j.jaip.2021.02.042. Epub 2021 Mar 4.
7
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30.
8
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab.
Ther Clin Risk Manag. 2019 Jul 10;15:869-875. doi: 10.2147/TCRM.S207402. eCollection 2019.
9
Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm.
Clin Transl Allergy. 2019 Jul 25;9:36. doi: 10.1186/s13601-019-0277-4. eCollection 2019.
10
Association of the blood eosinophil count with end-organ symptoms.
Ann Med Surg (Lond). 2019 Jul 9;45:11-18. doi: 10.1016/j.amsu.2019.06.015. eCollection 2019 Sep.
Zotero 插件